This Article Full Text Full Text (PDF) All Versions of this Article: 40/1/61    most recent 01.HYP.0000022061.12297.2Ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spencer, C. G.C. Articles by Lip, G. Y.H. Search for Related Content PubMed PubMed Citation Articles by Spencer, C. G.C. Articles by Lip, G. Y.H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB AMLODIPINE BESYLATE ATENOLOL BENDROFLUMETHIAZIDE Medline Plus Health Information Blood Pressure Medicines High Blood Pressure

(Hypertension. 2002;40:61.)
© 2002 American Heart Association, Inc.

Scientific Contributions

Von Willebrand Factor, Soluble P-Selectin, and Target Organ Damage in Hypertension

A Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Charles G.C. Spencer; David Gurney; Andrew D. Blann; D. Gareth Beevers; Gregory Y.H. Lip

From the Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, United Kingdom.

Correspondence to Prof G.Y.H. Lip, Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, B18 7QH, United Kingdom. E-mail G.Y.H.LIP{at}bham.ac.uk

To investigate the relationship between soluble markers of platelet, endothelial and rheological function, and target organ damage and their response to intensified management in a population of middle-age hypertensive patients at high risk of cardiovascular complications, we studied 382 consecutive patients (308 men; mean age, 63 years, SD 8) along with 60 normotensive controls free of cardiovascular disease. Patients were divided into those with target organ damage (TOD; n=107) and those free of end-organ damage. Plasma levels of soluble P-selectin (sP-sel), a marker of platelet activation, and von Willebrand factor (vWF), an index of endothelial damage/dysfunction (both enzyme-linked immunosorbent assay), and the rheological indices fibrinogen, plasma viscosity, hematocrit, platelet, and white cell count were measured. In 53 patients, variables were further measured after 6 months of intensified cardiovascular risk management. Patients with TOD had significantly higher vWF, 137 (SD 33) versus 125 (SD 33) IU/dL (P=0.002,) and a greater proportion of smokers, 31% versus 16% (P=0.002). There were no statistically significant differences in plasma viscosity, fibrinogen, hematocrit, white blood cell count, platelet count, or sP-sel between the 2 subgroups. In multivariate analysis, vWF was a significant independent predictor for TOD. After 6 months of intensified management in 53 patients who entered the trial, there were significant reductions in systolic blood pressure, total cholesterol, hematocrit, plasma viscosity, sP-sel, and vWF (all P<0.01) but no significant change in fibrinogen. In conclusion, there is a relationship between TOD and endothelial damage/dysfunction in hypertension. Intensified management results in improvements in hemorheology, endothelial and platelet function.

Key Words: target organ damage • endothelium • von Willebrand factor • fibrinogen • soluble P-selectin • rheology

This article has been cited by other articles:

				G. I Varughese, J. V Patel, J. Tomson, and G. Y H Lip Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation Heart, April 1, 2007; 93(4): 495 - 499. [Abstract] [Full Text] [PDF]

				E. Arikan and S. Sen Endothelial Damage and Hemostatic Markers in Patients with Uncomplicated Mild-to-Moderate Hypertension and Relationship with Risk Factors Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 147 - 159. [Abstract] [PDF]

				S. K. Nadar, A. D. Blann, S. Kamath, D. G. Beevers, and G. Y. H. Lip Platelet indexes in relation to target organ damage in high-risk hypertensive patients: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) J. Am. Coll. Cardiol., July 21, 2004; 44(2): 415 - 422. [Abstract] [Full Text] [PDF]

				D. N. Granger, T. Vowinkel, and T. Petnehazy Modulation of the Inflammatory Response in Cardiovascular Disease Hypertension, May 1, 2004; 43(5): 924 - 931. [Abstract] [Full Text] [PDF]

				A. D. Blann, S. K. Nadar, and G. Y.H. Lip The adhesion molecule P-selectin and cardiovascular disease Eur. Heart J., December 2, 2003; 24(24): 2166 - 2179. [Abstract] [Full Text] [PDF]

				S. Tsiara, M. Elisaf, I. A. Jagroop, and D. P. Mikhailidis Platelets as Predictors of Vascular Risk: Is There a Practical Index of Platelet Activity? Clinical and Applied Thrombosis/Hemostasis, July 1, 2003; 9(3): 177 - 190. [Abstract] [PDF]

				A. D. Blann, S. Nadar, and G. Y.H. Lip Pharmacological Modulation of Platelet Function in Hypertension Hypertension, July 1, 2003; 42(1): 1 - 7. [Abstract] [Full Text] [PDF]

				S. Nadar and G. Y. H. Lip Hypertension and the prothrombotic state J. Am. Coll. Cardiol., May 21, 2003; 41(10): 1847 - 1847. [Full Text] [PDF]

				G. Y.H. Lip Hypertension, Platelets, and the Endothelium: The "Thrombotic Paradox" of Hypertension (or "Birmingham Paradox") Revisited Hypertension, February 1, 2003; 41(2): 199 - 200. [Full Text] [PDF]